Treatment of children and adolescents with juvenile idiopathic arthritis and other pediatric rheumatic diseases has evolved. Where once there was only a limited arsenal of medications, with significant side effects and inadequate efficacy, today, with an increased understanding of the pathogenesis of these diseases, there is a wider variety of more targeted and effective treatments. TNF-α is a cytokine involved in a number of inflammatory pathways in pediatric rheumatic diseases. The emergence of biologic modifiers that target TNF-α has been pivotal in providing the ability to deliver early and aggressive treatment. Adalimumab, a recombinant monoclonal antibody to TNF-α, is an important therapeutic option, which affords children and adolescents with chronic illnesses an improved quality of life.
CITATION STYLE
Marzan, K. (2012). Role of adalimumab in the management of children and adolescents with juvenile idiopathic arthritis and other rheumatic conditions. Adolescent Health, Medicine and Therapeutics, 85. https://doi.org/10.2147/ahmt.s22607
Mendeley helps you to discover research relevant for your work.